Revance Therapeutics Inc (NASDAQ:RVNC)
| 31.47 Delayed Data As of Mar 23 |  -0.31 / -0.98%Today’s Change | 11.27 Today|||52-Week Range 36.61 | +70.48% Year-to-Date |
Latest RVNC News | Press Releases
No recent news for Revance Therapeutics Inc.
Today’s Trading
| Previous close | 31.78 |
| Today’s open | 32.05 |
| Day’s range | 31.08 - 32.87 |
| Volume | 26,738 |
| Average volume (3 months) | 1,450,297 |
| Market cap | $2.6B |
Data as of 4:00pm ET, 03/23/2023
Growth & Valuation
| Earnings growth (last year) | -17.63% |
| Earnings growth (this year) | +18.61% |
| Earnings growth (next 5 years) | +192.00% |
| Revenue growth (last year) | +70.40% |
| P/E ratio | NM |
| Price/Sales | 10.13 |
| Price/Book | 203.94 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| RAREUltragenyx Pharmaceu... | -0.31 | -0.83% |
| HCMHUTCHMED (China) Ltd | -0.37 | -2.54% |
| BHCValeant Pharmaceutic... | -0.30 | -3.96% |
| SAGESAGE Therapeutics In... | +0.40 | +0.95% |
Data as of 4:00pm ET, 03/23/2023
Financials
| Next reporting date | May 9, 2023 |
| EPS forecast (this quarter) | -$0.67 |
| Annual revenue (last year) | $132.6M |
| Annual profit (last year) | -$356.4M |
| Net profit margin | -268.87% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Nashville, Tennessee |
Forecasts
